|
The Cyprus Presidency has presented its priorities on health as follows:
In the field of public health, preparedness for and response to serious cross-border threats to health need to be improved and, hence, the Cyprus Presidency will pay particular attention to health security in the EU. The Council will continue its work on the proposal for a decision on cross border threats to health with the objective of strengthening internal EU structures, preparedness and response planning. In this context, discussions will focus on the regional dimension of health security and on the capacity building, especially in relation to the EU neighbouring countries.
The Presidency will aim to reach an agreement on the proposal for the Regulation establishing the 3rd Multiannual Programme of EU action in the field of health for the period 2014 – 2020, namely Health for Growth Programme, subject to the agreement on the new Multiannual Financial framework and in line with the objectives of Europe 2020 Strategy for sustainable and inclusive growth.
The Presidency will also address the issue of chronic diseases by highlighting the essential role of disease prevention, early diagnosis and health promotion programmes and by addressing main health determinants. Hence, conclusions will be prepared in order to emphasise healthy living across the lifecycle, leading to a healthy ageing process. The Presidency will also coordinate the EU position for the 5th Conference of Parties of the WHO Framework Convention on Tobacco Control to be held in November 2012. The important issue of organ donation and transplantation will also be dealt with by the Presidency, which will propose relevant Council conclusions.
The incident of the faulty implants highlighted the need to improve the control of medical devices production and of their placing on the market. In this respect, the Presidency will initiate the discussions on the revision of the medical devices legislation.
In the field of pharmaceuticals, the Presidency main objectives are to enhance the quality of information given to patients and to establish clear and transparent procedures. This will be pursued by advancing the discussions on the proposals for the revision of the Directive relating to transparency of measures regulating the pricing of medicinal products and the revision of the Directive on clinical trials.
For further information: http://www.cy2012.eu/en/page/home |
Print this page
Recommend this page
Report defect link